Recursion Pharmaceuticals
AI-driven drug discovery techbio (Nasdaq: RXRX) — Recursion OS 2.0 integrates multi-omic data, causal AI and high-throughput experimentation across the integrated Exscientia merger. FY2025 revenue trajectory in the tens-of-millions range with first AI-enabled clinical proof-of-concept in FAP and fifth program milestone with Sanofi.
The Business
Recursion Pharmaceuticals is a publicly-listed AI-driven drug discovery techbio (Nasdaq: RXRX) built on the Recursion OS 2.0 platform that integrates multi-omic data, causal AI and high-throughput experimentation. The product line is anchored on the platform itself plus an internal drug-discovery pipeline and a portfolio of pharmaceutical partnerships (Sanofi, Bayer, others) structured as upfront, milestone-based and royalty-based revenue. The company was founded on November 1, 2013 by Chris Gibson and Dean Li at the University of Utah, where Gibson developed the underlying technology during his MD/PhD work in Li’s lab. The November 2024 acquisition of Exscientia (deal valued at approximately $688M) combined two of the largest pre-existing AI-driven drug discovery platforms into a single integrated entity. Recursion is publicly listed on Nasdaq under ticker RXRX following the April 2021 IPO.
Customers and Distribution
Recursion is publicly listed and files 10-Q / 10-K reports with the SEC; Q2 2025 revenue $19.22M up 25% YoY driven by partnership milestones, with net loss widening to $171.9M in the same period. The FY2025 Q4 and full-year results announcement highlighted continued quarterly revenue growth, a smaller net loss and continued commentary on the AI-driven discovery platform with the first AI-enabled clinical proof-of-concept achieved in FAP and the fifth program milestone achieved with Sanofi. Distribution is via pharmaceutical-partnership procurement (Sanofi multi-program partnership, Bayer partnership and others) structured around upfront, milestone-based and royalty-based revenue; the partnership-revenue mix and milestone-receipt cadence are the principal commercial variables disclosed in quarterly 10-Q filings. The combined post-Exscientia entity carries materially-larger R&D commitments than the pre-merger Recursion baseline; cash runway against the R&D burn rate is the principal financial-execution variable.
Model Strategy
Recursion is a Verticals-first AI play under the IM Framework eight-trajectories taxonomy: the strategic bet is that AI-driven drug discovery is a defensible vertical primitive built on Recursion OS 2.0, the Exscientia merger integration and the multi-omic / high-throughput-experimentation platform that pre-dated current frontier-model adoption. The platform integrates phenotypic screening (Recursion heritage), generative chemistry (Exscientia heritage), multi-omic data integration and causal AI for target identification and lead optimisation. The NVIDIA strategic partnership on the BioHive supercomputer infrastructure is the canonical compute-resource anchor. Above the platform layer, the pharmaceutical-partnership procurement (Sanofi, Bayer) is the principal commercial distribution channel; the internal pipeline is the principal value-capture pathway alongside partnership-revenue.
At A Glance
The Numbers
Annualised revenue
Active pharma partnerships
Headcount (FTE)
Leadership Team
Recursion is in active CEO transition with Najat Khan having taken over from co-founder Chris Gibson effective January 2026; Gibson transitioned to Chairman and announced in April 2026 that he will not seek re-election to the board after June 2026. The Khan-led strategic refocus (announced at the post-Exscientia merger reorganisation) concentrates resources on the highest-rationale programs with near- and long-term clinical potential.
IM Framework Scoring
IM’s structured assessment of Recursion Pharmaceuticals’s competitive position. The summary below is the headline; expand “Show the full analyst-grade analysis” near the bottom for the per-dimension reasoning and evidence. Methodology →
Funding History
| Date | Round | Raised | Post-money | Lead investor(s) |
|---|---|---|---|---|
| Apr 2021 | IPO | ~$502M | — | Nasdaq listing (ticker RXRX) April 16, 2021 |
| Nov 2024 | Exscientia merger | Stock-and-cash (~$688M deal) | — | Acquisition of Exscientia closed November 2024 in the biggest life-sciences AI merger to that point |
| 2024 | Sanofi partnership extension | Multi-program milestones | — | Pharmaceutical partnership for AI-driven target discovery; fifth program milestone achieved in 2025 |
| Nov 2021 | NVIDIA partnership | Strategic | — | NVIDIA strategic partnership on the BioHive supercomputer infrastructure |
Recursion is a publicly-listed company (Nasdaq: RXRX) listed in April 2021. Pre-IPO cumulative equity ~$420M (Series B $60M 2017 + Series C $121M 2019 + Series D $239M Sep 2020); IPO gross $501.8M / net $462.6M April 2021. The November 2024 all-stock Exscientia merger (~$688M deal value) added the combined entity revenue base, R&D pipeline and cash position. Funding-to-date is an ill-defined metric for a public company; refer to the 10-K cash/equivalents and accumulated paid-in-capital disclosures on ir.recursion.com as the canonical primary source. A12 audit June 2026 reset the tracker to decline-to-publish on funding_to_date for this listed-company entry.
Competitive Landscape
| Competitor | Positioning | Distribution edge | Threat profile |
|---|---|---|---|
| Isomorphic Labs (Alphabet (NASDAQ: GOOGL)) |
Alphabet-funded AI drug discovery spun out of DeepMind — AlphaFold-derived structure prediction at the core, pursued through pharma partnerships with Eli Lilly and Novartis rather than its own clinical pipeline. | Big-Pharma partnership model (Lilly, Novartis) backed by Alphabet capital and DeepMind talent; no public-market disclosure pressure or commercial-stage burn. | High — DeepMind-anchored AI-driven drug discovery with AlphaFold and downstream protein-structure capabilities; structural-symmetric public-AI competitor with Alphabet capital backing. |
| Generate Biomedicines / Insitro | AI-native biotech peers — Generate focuses on generative protein design via its Chroma model, Insitro on ML-driven target discovery from human genetic and phenotypic data. Narrower platform scope than Recursion’s Recursion-OS-plus-Exscientia stack. | Pharma R&D partnerships (Generate with Amgen, Insitro with BMS / Gilead) plus internal pipelines; private-company status means less disclosure pressure than RXRX. | High — well-funded private techbio competitors with comparable AI-driven drug discovery positioning; head-to-head on pharmaceutical-partnership procurement and platform-positioning. |
| Schrodinger (NASDAQ: SDGR) |
Public-listed (Nasdaq: SDGR) physics-based computational chemistry incumbent — software licensing plus a co-development drug pipeline. The longest-standing computational drug-discovery moat in the cohort. | Software licensing into virtually every Big Pharma and large biotech (the LiveDesign platform is industry-standard), plus collaboration agreements that fund the proprietary pipeline. | Medium-High — public-listed computational chemistry platform with broader physics-based simulation positioning; competes on enterprise pharmaceutical procurement and adjacent on AI-driven discovery. |
| Big Pharma in-house AI (Various) |
Roche, Pfizer, AstraZeneca, Lilly, Novartis, Sanofi all running internal AI / ML drug-discovery groups; foundation-model partnerships (Lilly-Isomorphic, Roche-NVIDIA BioNeMo, Sanofi-OWKIN) plus internal platform teams. | Captive: Big Pharma owns the pipeline, the trial infrastructure, the data and the commercial channel; uses AI vendors as tools rather than acquiring them. | Medium-High — Pfizer, AstraZeneca, Novartis, Sanofi and others are all building in-house AI-driven drug discovery capabilities; structural risk on whether techbio platform vendors retain procurement budget or whether Big Pharma in-houses the capability. |
| Chai Discovery / EvolutionaryScale | Foundation-model labs for biology — Chai-1 / Chai-2 structure-prediction models, EvolutionaryScale’s ESM3 frontier protein language model. AI-first labs pitching the next generation of biological reasoning, not vertically integrated drug companies. | Open-weight model releases (ESM, Chai-1) plus API and enterprise licensing into pharma R&D groups; positioned upstream of Recursion’s integrated-platform model. | Medium — protein-language-model and structure-prediction startups competing on the upstream protein-design layer; flanking risk on the drug-discovery AI platform layer. |
Potential Risks
Drug-discovery commercial cycle length
The fundamental commercial reality of drug discovery is that platform-adoption metrics and quarterly revenue are decoupled from clinical-milestone outcomes that play out across multi-year cycles. Recursion platform-utilisation can scale through pharmaceutical-partnership cadence but the company commercial outcomes depend on clinical proof-of-concept readouts. The FAP AI-enabled clinical proof-of-concept and the Sanofi fifth-program milestone are the canonical near-term watch-items.
Big Pharma in-house AI substitution
Pfizer, AstraZeneca, Novartis, Sanofi and other Big Pharma companies are all building in-house AI-driven drug discovery capabilities. The structural risk is whether techbio platform vendors (Recursion, Isomorphic Labs, Generate Biomedicines, Insitro) retain pharmaceutical-partnership procurement budget or whether Big Pharma in-houses the capability. Recursion hedge is the Exscientia merger integration and the depth of the Recursion OS 2.0 platform.
Post-merger integration and strategic refocus execution
The Exscientia merger closed November 2024 and the post-merger integration plus the January 2026 Najat Khan CEO transition mark a strategic refocusing on the highest-rationale programs. Execution risk on the refocus (portfolio rationalisation, integrated R&D leadership, cash-deployment prioritisation) is the principal organisational-scale variable.
Cash runway against R&D commitments
The combined post-Exscientia entity carries materially-larger R&D commitments than the pre-merger Recursion baseline. Cash runway against the R&D burn rate is the principal financial-execution variable; the FY2025 10-K and ongoing 10-Q disclosures are the canonical reference for cash position and R&D spend cadence.
Public-market valuation framing and biotech cycle
Recursion as a publicly-listed techbio is subject to the broader biotech-stock cycle and to specific AI-drug-discovery narrative cycles. Public-market valuation framings have moved materially through 2024-2026 around clinical-milestone disclosures, partnership announcements, and broader biotech-sector sentiment. The structural risk is whether the public-market framing reflects platform-adoption progress or whether it amplifies biotech-cycle noise.
Recent IM Coverage
- AI Tracker — methodology May 2026.
- Healthcare AI sector overview May 2026.
Show recent press coverage of Recursion Pharmaceuticals
- Q1 2026 — Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (Recursion IR)
- Nov 2025 — Recursion CEO Chris Gibson out as company head after 12 years (STAT News)
- Nov 2025 — Recursion Announces CEO Transition Plan to Drive Next Phase of Growth (Recursion IR)
- 2026 — After a decade of hype, Najat Khan is bringing Recursion back down to earth (FierceBiotech)
- Nov 2024 — Recursion and Exscientia Two Leaders in AI Drug Discovery Have Officially Combined (Recursion IR)
- Apr 2026 — Recursion Announces Board Transition (GlobeNewswire)
- 2024 — Recursion and Exscientia merge in $688M deal to create consolidated AI-driven drug discovery platform (Drug Discovery Trends)
Show the source register for the figures on this page
IM operates a primary-source-where-possible discipline. The figures above come from:
- Revenue: Recursion is publicly listed and files 10-Q / 10-K reports with the SEC. Q2 2025 revenue $19.22M up 25% YoY driven by partnership milestones; net loss widened to $171.9M in the same period. The FY2025 Q4 and full-year results announcement highlighted quarterly revenue growth and a smaller net loss with continued AI-driven discovery platform commentary. The 10-K filing is the canonical primary reference for annual financials.
- Pipeline and partnerships: Recursion has multi-program pharmaceutical partnerships with Sanofi (fifth program milestone achieved in 2025) and Bayer among others. The November 2024 Exscientia merger integrated the combined pipeline; first AI-enabled clinical proof-of-concept achieved in FAP per CEO commentary in the Q4 2025 results announcement.
- Headcount: Recursion 10-K filing discloses headcount as part of the annual reporting. The combined post-Exscientia entity headcount is integrated; we reference the Q4 2025 results announcement and the SEC 10-K as the canonical primary source.
- Public capital structure: Recursion is publicly listed on Nasdaq under ticker RXRX following the April 2021 IPO. The November 2024 Exscientia merger was a stock-and-cash transaction valued at approximately $688M per Drug Discovery Trends coverage. Cash position, secondary equity offerings and milestone-receipt cadence are disclosed in the 10-Q and 10-K filings on SEC Edgar.
Methodology & Disclaimer
For metric definitions, source-tier hierarchy, and decline-to-publish rules, see the tracker methodology. Confidence dots (• green / • amber / • red) follow the same convention as the AI Tracker.
Spotted a figure you believe is wrong? Send corrections to info@informationmatters.net.
Information Matters Framework scores are the considered opinion of the IM team — human and AI — applied to publicly-available evidence under a disclosed methodology. They are not statements of fact about the companies scored and they are not investment advice.
